Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

21. Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop

Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop 28447053 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi (...) -feedback loop. 18 10.21037/tgh.2017.03.02 A working theoretical model for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGIDs) does not exist, hampered by the lack of any clear cut invention that address all symptom and signs of the disease. Reports of cessation of symptom and signs of both major types of IBS have been published using a non-systemic, topically active agent-high potency polymerized cross-linked sucralfate (HPPCLS). The unique clinical effect of this non

Translational gastroenterology and hepatology2017 Full Text: Link to full Text with Trip Pro

22. The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment.

The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. 28070348 2017 01 10 2017 02 24 2 1 2015 Jan Health psychology open Health Psychol Open The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. 2055102914564583 10.1177/2055102914564583 Hypnotherapy has been reported as being beneficial in the treatment of irritable bowel syndrome (IBS). We aimed to test the hypothesis (...) that patients with IBS treated 'holistically' by hypnosis (i.e. by combined psychological and physiological symptom imagery) would have greater improvement in their IBS symptoms than patients treated by hypnosis using standard 'gut-directed' hypnotherapy, and both would be superior to simple relaxation therapy. Patients (n = 51) with Rome II criteria were randomised to 'individualised' (holistic) hypnotherapy, standard 'gut-directed' hypnotherapy or relaxation therapy for a period of 11 weeks with two

Health psychology open2017 Full Text: Link to full Text with Trip Pro

26. Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea

Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 21 July 2016 EMA/549473/2016 Committee for Medicinal Products for Human Use (...) mass index BSS Bristol Stool Scale CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration CNS central nervous system CSR clinical study report EMA European Medicines Agency EU European Union FDA US Food and Drug Administration GERD gastroesophageal reflux disease GI gastrointestinal IBS irritable bowel syndrome IBS-d diarrhea-predominant irritable bowel syndrome IBS-m irritable bowel syndrome, where a mixture of constipation and diarrhea is predominant IBS-QoL

European Medicines Agency - EPARs2016

27. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women 26551550 2016 01 25 2016 06 03 2016 01 25 1528-0012 150 2 2016 Feb Gastroenterology Gastroenterology Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. 358-66.e8 10.1053/j.gastro.2015.10.047 S0016-5085(15)01584-X Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients (...) with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women. We performed a prospective study of 576 female outpatients with IBS-D (according to the Rome III criteria), from February 2013 through February 2014, at 70 academic Gastroenterology Departments in Japan

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

28. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome 26883355 2016 02 17 2018 11 13 2194-7791 3 1 2016 Dec Molecular and cellular pediatrics Mol Cell Pediatr Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. 11 10.1186/s40348-016-0036-8 Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS (...) biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial fermentation, and genetics. The molecular and cellular mechanisms of these factors are being actively investigated. In this mini-review, we present updates of these mechanisms and, where possible, relate the findings to childhood IBS. Mechanistic elucidation may lead to the identification of biomarkers

Molecular and cellular pediatrics2016 Full Text: Link to full Text with Trip Pro

29. Genetics of irritable bowel syndrome

Genetics of irritable bowel syndrome 26873717 2016 02 13 2018 11 13 2194-7791 3 1 2016 Dec Molecular and cellular pediatrics Mol Cell Pediatr Genetics of irritable bowel syndrome. 7 10.1186/s40348-016-0038-6 Irritable bowel syndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life and poses considerable repercussions on health and socioeconomic (...) systems. There is a heritable component in IBS, and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight into the pathophysiology. However, although some gene-hunting efforts have been conducted and a few risk genes proposed, IBS genetic research is lagging behind compared to other complex diseases. In this mini-review, we briefly summarize existing genetic studies, discuss the main challenges in IBS genetic research, and propose

Molecular and cellular pediatrics2016 Full Text: Link to full Text with Trip Pro

30. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea. Methods We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose (...) of 75 mg or 100 mg) or placebo twice daily for 26 weeks (IBS-3002 trial) or 52 weeks (IBS-3001 trial). The primary end point was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of the days from weeks 1 through 12 and from weeks 1 through 26. Results For weeks 1 through 12, more patients in the eluxadoline groups (75 mg and 100 mg) than in the placebo group reached the primary end point (IBS

NEJM2016

31. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial

Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial 26255043 2015 10 30 2016 04 07 2016 07 27 1528-0012 149 6 2015 Nov Gastroenterology Gastroenterology Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. 1399-1407.e2 10.1053/j.gastro.2015.07.054 S0016-5085(15)01086-0 A diet with reduced content of fermentable short-chain (...) carbohydrates (fermentable oligo-, di-, monosaccharides, and polyols [FODMAPs]) has been reported to be effective in the treatment of patients with irritable bowel syndrome (IBS). However, there is no evidence of its superiority to traditional dietary advice for these patients. We compared the effects of a diet low in FODMAPs with traditional dietary advice in a randomized controlled trial of patients with IBS. We performed a multi-center, parallel, single-blind study of 75 patients who met Rome III

EvidenceUpdates2016

32. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines

Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines | CADTH.ca Find the information you need Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Trimebutine Maleate and Pinaverium Bromide (...) for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Published on: November 30, 2015 Project Number: RC0721-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of trimebutine maleate for the treatment of patients with irritable bowel syndrome? What is the clinical effectiveness and safety of pinaverium bromide for the treatment of patients with irritable bowel syndrome

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

33. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway.

Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Vitenskapelig artikkel (...) Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Published 27/11/2015 Michalsen VL, Vandvik PO, Farup PG.Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway.Health Qual Life Outcomes. 2015 Jul 30;13:113. doi: 10.1186/s12955-015-0311-8. PMID: 26223784. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study

The Norwegian Knowledge Centre for the Health Services2015

34. Irritable bowel syndrome: dietary interventions.

Irritable bowel syndrome: dietary interventions. Irritable bowel syndrome: dietary interventions. - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Vitenskapelig artikkel Irritable bowel syndrome: dietary interventions. Published 27/11/2015 Ford AC, Vandvik PO.Irritable bowel syndrome: dietary interventions.BMJ Clin Evid (...) . 2015 Jul 30;2015. pii: 0410. PMID: 26226510. Irritable bowel syndrome: dietary interventions.. Vitenskapelig artikkel – 2015. Key messages INTRODUCTION: The prevalence of irritable bowel syndrome (IBS) varies depending on the criteria used to diagnose it, but it ranges from about 5% to 20%. IBS is associated with abnormal gastrointestinal motor function and enhanced visceral perception, as well as psychosocial and genetic factors. People with IBS often have other bodily and psychiatric symptoms

The Norwegian Knowledge Centre for the Health Services2015

35. Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial.

Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. 26435825 2015 10 05 2015 10 05 2017 02 20 7 5 2015 Sep Electronic physician Electron Physician Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. 1255-60 10.14661/1255 Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders (...) . The most effective species and the most appropriate doses are still unknown. The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients. In a controlled, double blind, randomized trial, patients with IBS diagnosed by Rome III criteria from August 2012 to September 2012 at Dr. Sheikh Hospital, Mashhad University of Medical Sciences, Iran, were assigned to one of two groups, i.e., intervention and control groups. For four weeks, the intervention group

Electronic physician2015 Full Text: Link to full Text with Trip Pro

36. Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what?

Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what? 2015. DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation DAR No 4: Linaclotide (...) . Constella® in the symptomatic management of irritable bowel syndrome with constipation Content tools Share it The indication was granted...so what? Although authorized for irritable bowel syndrome with constipation it offers only symptomatic relief. In the best of cases, one in five patients can benefit from treatment. On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases. There are no available studies evaluating

Drug and Therapeutics Bulletin of Navarre (Spain)2015

37. Irritable bowel syndrome: new and emerging treatments.

Irritable bowel syndrome: new and emerging treatments. Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial (...) , and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritable bowel syndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines

BMJ2015

38. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try

NIHR HTA programme2015 Full Text: Link to full Text with Trip Pro

39. An antiemetic for irritable bowel syndrome?

An antiemetic for irritable bowel syndrome? An antiemetic for irritable bowel syndrome? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics An antiemetic for irritable bowel syndrome? View/ Open Date 2014-10 Format Metadata Abstract An antiemetic for irritable bowel syndrome? A drug used for cancer patients may provide (...) some relief to patients with IBS. Practice changer: Consider prescribing ondansetron up to 24 mg/d for patients who have irritable bowel syndrome with diarrhea (IBS-D). URI Part of Citation Journal of Family Practice, 63(10) 2014: 600-602. Collections hosted by hosted by

PURLS2015

40. Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women

Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women Viberzi (eluxadoline) Tablets U.S. Department of Health and Human Services Search FDA Submit search Viberzi (eluxadoline) Tablets Viberzi (eluxadoline) Tablet Company: Furiex Pharmaceuticals, Inc. Application No.: 206940 Approval Date: 05/27/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2015